Hoffmann-la Roche
Clinical trials sponsored by Hoffmann-la Roche, explained in plain language.
-
New drug cocktail aims to supercharge weight loss in obesity trial
Disease control Not yet recruitingThis study tests whether combining two experimental drugs, petrelintide and enicepatide, helps adults with obesity or overweight lose more weight than taking either drug alone or a placebo. About 486 participants will receive different doses or a placebo for several months. The g…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New targeted pill aims to keep KRAS lung cancer from returning after surgery
Disease control Not yet recruitingThis study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New Weight-Loss drug enicepatide enters first human tests in china
Disease control Not yet recruitingThis Phase 1 trial tests the safety and tolerability of enicepatide, a potential weight-loss drug, in 36 generally healthy Chinese adults with a BMI of 23 or higher. Participants will receive either the drug or a placebo by injection, and researchers will monitor side effects and…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New MS drug trial for kids: could ocrelizumab help?
Disease control Not yet recruitingThis study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a sh…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New study tracks Risdiplam's Real-World impact on spinal muscle atrophy
Knowledge-focused Not yet recruitingThis study will observe 30 children with type I or type II spinal muscle atrophy who are taking risdiplam. Researchers will track motor function improvements over 24 months using standard tests. The goal is to see how well the drug works in everyday medical practice.
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC